Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

BackgroundThe balance of risks and benefits with using proton pump inhibitors (PPIs) versus histamine-2 receptor blockers (H2RB) for stress ulcer prophylaxis in patients who are invasively ventilated in the intensive care unit (ICU) is uncertain.ObjectiveTo describe the study protocol and statistical analysis plan for the Proton Pump Inhibitors versus Histamine-2 Receptor Blockers for Ulcer Prophylaxis Therapy in the Intensive Care Unit (PEPTIC) study.Design, setting and participantsProtocol for a prospective, multicentre, randomised, open-label, cluster crossover, registry-embedded trial to be conducted in 50 ICUs in Australia, Canada, Ireland, New Zealand and the United Kingdom. The PEPTIC study will compare two approaches to stress ulcer prophylaxis in mechanically ventilated adults implemented at the level of the ICU. One approach is to use PPIs as the default therapy and the other approach is to use H2RBs as the default therapy when stress ulcer prophylaxis is prescribed. Each ICU, by random allocation, will use one approach for 6 months and will then switch to the opposite approach for the next 6 months. The PEPTIC study began recruitment in August 2016 and will complete recruitment in January 2019.Main outcome measuresThe primary end point will be in-hospital mortality. Secondary outcomes include clinically significant upper gastrointestinal bleeding, Clostridium difficile infection, ICU length of stay and hospital length of stay.Results and conclusionsThe PEPTIC study will compare the effect on in-hospital mortality of implementing, at the level of the ICU, the use of PPI as the preferred agent for stress ulcer prophylaxis in mechanically ventilated adults in the ICU with using H2RB as the preferred agent.Trial registrationAustralian and New Zealand Clinical Trials Registry (ANZCTRN 12616000481471).



Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine

Publication Date





182 - 189


Intensive Care Unit, Wellington Regional Hospital, Wellington, New Zealand.


Australian and New Zealand Intensive Care Society Clinical Trials Group on behalf of the PEPTIC investigators, Humans, Clostridium Infections, Stomach Ulcer, Gastrointestinal Hemorrhage, Histamine H2 Antagonists, Respiration, Artificial, Length of Stay, Registries, Hospital Mortality, Prospective Studies, Cross-Over Studies, Research Design, Intensive Care Units, Canada, Australia, Ireland, New Zealand, Proton Pump Inhibitors, United Kingdom